The authors review the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with glucagon-like peptide 1 receptor (GLP1R) agonists, and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development.
[Nature Reviews Cardiology]
